DEFA14A: Keros Therapeutics Defends Strategic Review Amidst Activist Investor Pressure

Keros Therapeutics is actively pursuing a strategic review to maximize stockholder value, while facing pressure from ADAR1 Capital, which the company claims is disruptive to the process.

Summary

• Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to dysfunctional signaling of the TGFfamily of proteins.
• The company's pipeline includes elritercept (KER-050), outlicensed to Takeda for $200 million upfront and up to $1.1 billion in potential milestones, KER-065 (Phase 2 expected 1Q26), and cibotercept (KER-012), with potential development in pulmonary arterial hypertension (PAH).
• Keros's Board is undertaking a comprehensive review of strategic alternatives, including a potential sale, business combination, continued investment in the pipeline, and/or return of excess capital, with an interim update expected by June 9, 2025.
• The company is responding to pressure from ADAR1 Capital, which holds a ~13.3% ownership stake, and believes ADAR1's demands are self-serving and disruptive to the strategic review process.
• Keros emphasizes its strong cash position, experienced management team, and the qualifications of its Board to oversee the strategic process.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While highlighting positive aspects like the Takeda deal and pipeline progress, it also acknowledges stock underperformance and addresses challenges from an activist investor. The focus on strategic review suggests uncertainty but also potential for positive change.

Positives

• Keros has a strong cash position and a disciplined approach to capital allocation.
• The company has a seasoned management team with extensive experience in the TGFspace.
• Elritercept's outlicensing to Takeda validated Keros's scientific approach and commitment to capital-efficient development.
• KER-065 has shown promising preclinical and Phase 1 data, with positive feedback from leading DMD experts.
• The Board is actively engaged in a strategic review process to maximize stockholder value.
• The company has a refreshed Board with a mix of skills to drive value creation and strong corporate governance practices.

Negatives

• Keros acknowledges the underperformance of its stock price, driven by the cibotercept clinical setback.
• The company faces pressure from ADAR1 Capital, which is attempting to influence the strategic direction of the company.
• There were four cases of fatal treatment-emergent adverse events (TEAEs) in the elritercept trial, though deemed unrelated to treatment.
• The company is managing the potential impact of ADAR1's actions on the ongoing strategic review process.

Risks

• The strategic alternatives review process may not achieve the desired objectives.
• The terms, structure, benefits, and costs of any strategic transaction are uncertain.
• The strategic alternatives review and its announcement could have an adverse effect on the company's ability to retain and hire key personnel and maintain relationships with partners.
• The strategic alternatives review could divert the attention and time of the company's management.
• Keros's ability to raise additional funding to complete the development and commercialization of its product candidates is a risk.
• Keros is dependent on the success of its product candidates, cibotercept, KER-065, and elritercept.
• Competition from third parties developing products for similar uses poses a risk.
• Keros's ability to obtain, maintain, and protect its intellectual property is a risk.
• Keros is dependent on third parties in connection with manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros is focused on maximizing stockholder value through a strategic review process, advancing its pipeline, and making data-driven decisions regarding the development of its product candidates. The company expects to report data from the Phase 2 TROPOS trial in the second quarter of 2025 and plans to evaluate the appropriate development strategy for cibotercept following that data readout.

Management Comments

• The Keros Board acknowledges the underperformance of our stock price, driven by the cibotercept clinical setback, and is laser focused on repositioning Keros for long-term value creation through the strategic review process.
• We believe ADAR1s misleading campaign is a threat to this strategic alternatives review process, and any disruption to our current highly qualified Board would jeopardize the process underway to maximize stockholder value.

Industry Context

Keros operates in the competitive biopharmaceutical industry, focusing on rare hematology and neuromuscular diseases. The company compares itself to peers such as GERN, DYN, TRDA, KURA, and DNTH. The strategic review process and engagement with activist investors are common occurrences in the biotech sector, as companies seek to maximize stockholder value and navigate clinical and regulatory challenges.

Comparison to Industry Standards

• Keros compares its board's investor representation (44%) favorably to the median of its performance peers (~17%) and proxy peers (~13%).
• The company highlights its outlicensing deal with Takeda as a validation of its scientific approach, similar to other biotech companies that partner with larger pharmaceutical firms to advance their pipelines.
• The document references taldefgrobep alfa, a myostatin inhibitor being developed for DMD, to differentiate KER-065's dual inhibition mechanism.
• The company's strategic review process is a common practice among biotech companies facing stock price pressures or seeking to unlock value.

Stakeholder Impact

• The strategic review process and potential outcomes could significantly impact stockholders, employees, and other stakeholders.
• The company's focus on developing novel therapeutics aims to benefit patients with unmet medical needs.
• The outlicensing agreement with Takeda could lead to broader access to elritercept for patients globally.
• The company's engagement with ADAR1 Capital could influence the future direction and value of the company.

Next Steps

• Keros intends to provide a preliminary update regarding the status of the strategic review process no later than June 9, 2025.
• The company plans to engage with regulatory authorities starting in 3Q25 regarding KER-065.
• Keros expects to initiate a Phase 2 clinical trial of KER-065 in patients with DMD in 1Q26, subject to regulatory interactions.
• The company will evaluate the appropriate development strategy for cibotercept following the data readout from the Phase 2 TROPOS trial in the second quarter of 2025.

Key Dates

Keywords

strategic review, elritercept, KER-065, cibotercept, ADAR1, Takeda, DMD, MDS, stockholder value, biopharmaceutical